Gilead Sciences Inc’s Chief Scientific Officer John McHutchison will leave the company next month, the company announced Wednesday. McHutchison, who is also Gilead’s head of research and development, joined the pharmaceutical giant in 2010 and was named chief scientific officer in March 2018. During his time at Gilead, he oversaw the development of several hepatitis B and C treatments, as well as the company’s expansion into oncology with the development of Zydelig.
Gilead also announced other changes to its senior leadership team: Chief Patient Officer Greg Alton and Executive Vice President of Human Resources Katie Watson will be leaving, as well. Jyoti Mehra, currently vice president of human resources, will take Watson’s place.
Shares of Gilead fell 0.4% in premarket trade on the news. The stock has gained 7% in the year to date through Tuesday, while the S&P 500 has gained 19.8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- Twitter suspends China’s state-backed accounts trying manipulate public conversation about Hong Kong protests - August 19, 2019
- The Moneyist: My elderly father refuses to use his oxygen tank — will our stepmother get all his money if he dies without a will? - August 19, 2019
- The Moneyist: My aunt is stealing my dead mother’s Social Security and persuaded my hospitalized father to sign over power of attorney - August 19, 2019